Your session is about to expire
← Back to Search
Carvedilol for Cardiomyopathy in Breast Cancer Patients (TACTIC Trial)
TACTIC Trial Summary
This trial is testing whether a beta blocker called carvedilol can help protect the hearts of breast cancer patients taking trastuzumab-based HER2-directed therapy, either by starting it when significant heart function decline or early signs of heart injury are noted, or preventatively before beginning trastuzumab-based therapy.
TACTIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTACTIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TACTIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am taking ACE inhibitors or ARBs for high blood pressure, diabetes, or kidney disease.Your heart's pumping ability is less than 50%.I am currently taking medication for heart rhythm problems.I have a history of heart failure or have been diagnosed with cardiomyopathy.I am taking beta-blockers for heart disease.I have asthma and use daily asthma medication.I am currently receiving treatment for a cancer that is not breast cancer.Your blood pressure is consistently below 90 mmHg when measured three times.Your heart beats less than 50 times per minute during screening.I am 18 years old or older.I am scheduled for a treatment targeting HER2, excluding Nerantinib and Lapatinib.My breast cancer has spread to distant parts of my body.You have a certain type of heart block unless you have a pacemaker.I have or had a condition where my heart beats irregularly.I have severe liver problems.I have a new or returning HER2+ breast cancer and plan to treat it to cure.You cannot tolerate beta-blocker medication.
- Group 1: Pre-Emptive Strategy
- Group 2: Reactive Strategy
- Group 3: Standard of Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Carvedilol met all the necessary safety requirements for public consumption?
"Carvedilol's power rating sits at a 2. While there is some evidence backing its safety, none of the available data supports carvedilol's efficacy."
Are there other similar test programs that have used Carvedilol before?
"At the moment, 29 different clinical trials are underway to research carvedilol. 7 of those live clinical trials are in Phase 3. Orlando, Florida hosts the majority of trials for this treatment, but there are 978 locations running studies for it in total."
What are the common illnesses that Carvedilol is used to manage?
"Carvedilol's therapeutic benefits include reducing hypertension and treating heart failure, hypesthesia, and left ventricular dysfunction."
How many test subjects are in this experiment?
"In order to have this study be feasible, 450 individuals who meet the pre-set inclusion criteria must enroll. Some of the places where these people can join the trial are Mayo Clinic in Phoenix, Arizona and Mayo Clinic in Rochester, Minnesota."
Are researchers still looking for participants in this trial?
"The clinical trial is currently enrolling patients, with the most recent update on August 25th, 2022. The listing was first posted on August 21st, 2019."
Share this study with friends
Copy Link
Messenger